Advertisement

Picture [iito] Back into Ad 650x80px
Document › Details

Virometix AG. (3/12/20). "Press Release: Virometix Announces Initiation of Phase 1 Clinical Trial with Its V-306 Vaccine Candidate". Schlieren.

Region Region Belgium
Organisations Organisation Virometix AG
  Organisation 2 FAMHP (Federal Agency for Medicines and Health Products, Belgium)
  Group Belgium (govt)
Products Product V-306 RSV vaccine (Virometix)
  Product 2 Synthetic Virus-Like Particle technology (SVLP technology)
Person Person Sumeray (formerly Casse), Anna (Virometix 201902– CEO before Alacrita + BioVault + Ariad Europe + Novartis + ADL)
     


Virometix, a privately held Swiss biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and oncology diseases, is pleased to announce that the Belgian health authority, FAMHP, has approved the company’s clinical trial application for the first-in-human phase 1 study of its respiratory syncytial virus (RSV) vaccine candidate, V-306 in healthy volunteers. Funding has been secured and activities are underway to initiate the trial in the coming weeks.

RSV is a seasonal virus infection and the most common cause of serious acute lower respiratory infection. Infants and young children, as well as the elderly and immunocompromised are particularly at risk. No vaccine has been approved for the prevention of RSV infection. The market opportunity for RSV is estimated to reach $5.4 billion by 2028(1).

Anna Sumeray, Chief Executive Officer of Virometix, commented: “We are excited to be entering the clinic with V-306. Considerable efforts over the last few years to develop this innovative synthetic viruslike particle (SVLP) platform have resulted in a vaccine candidate that has the potential to protect vulnerable patients from the serious morbidity and mortality associated with RSV infection. We are looking forward to generating the first clinical data over the next few months.”

Professor Paul-Henri Lambert, Centre of Vaccinology in the Department of Pathology and Immunology at University of Geneva and Scientific Advisor to Virometix, commented: “I am enthusiastic about the underlying SVLP technology and its potential to effectively stimulate a protective immune response without the need for adjuvants. V-306 has the potential to induce specific antibodies that are known to neutralise the virus. We will await the results of the Phase 1 study with great interest.”


Enquiries: Anna Sumeray, CEO Virometix
anna.sumeray@virometix.com


About the Phase 1 trial with V-306

The phase 1 clinical trial will be a prospective double-blind randomized placebo-controlled study. A total of 60 healthy female subjects of child-bearing age will be included. V-306 or placebo will be administered by intra-muscular injection as an initial dose, followed by a boost dose 56 days later. Subjects will be split into 3 equally sized dose cohorts, with each cohort receiving an increased dose of V-306 or placebo. An independent data safety monitoring board will supervise the trial and approve enrolment of subjects into the next dose cohort after review of safety data. The primary objective of the study will be to establish the safety profile of V-306 and secondary objectives will include an evaluation of the immunogenicity of V-306. Subjects will be followed for one year after the initial dose of V-306.


About Virometix

Virometix AG is a privately held Swiss biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infections and cancer. In an increasingly global world, there is a considerable medical need for vaccines to combat infectious as well as a number of chronic human diseases, including cancer. Rational molecular design, chemical synthesis and Virometix' proprietary “Synthetic Virus-Like Particle” platform technology allow for the rapid production and optimization of vaccine candidates with the potential to demonstrate superior properties in terms of safety, efficacy and stability.

For more information about Virometix AG please visit: https://www.virometix.com /


(1) Source: GlobalData https://www.globaldata.com/global-rsv-market-set-to-reach-5-39bn-by2028-driven-by-new-product-launches/

   
Record changed: 2020-07-13

Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

More documents for Virometix AG


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioPharm America 2020 Digital Event BEU2020 650x81




» top